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Blocking  of  amygdaloid  TRPC4/C5  attenuated  neuropathic  hypersensitivity.
Blocking  of  amygdaloid  TRPC4/C5  attenuated  affective-like  neuropathic  pain.
In  healthy  rats,  blocking  amygdaloid  TRPC4/C5  failed  to inﬂuence  pain  behavior.
Amygdaloid  TRPC4/C5  contributes  to maintenance  of  neuropathic  pain.
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a  b  s  t  r  a  c  t
Pain  per  se  may  increase  anxiety  and  conversely,  anxiety  may  increase  pain.  Therefore,  a positive  feed-
back  loop  between  anxiety  and pain  possibly  contributes  to pain  and  suffering  in  some  pathophysiological
pain  conditions,  such  as  that  induced  by  peripheral  nerve  injury.  Recent  results  indicate  that  transient
receptor  channels  4  and  5 (TRPC4/C5)  in the  amygdala  have  anxiogenic  effects  in  rodents,  while  their  role
in  chronic  pain  conditions  is not  known.  Here,  we  studied  whether  the  amygdaloid  TRPC4/C5  that  are
known  to have  anxiogenic  properties  contribute  to the  maintenance  of  sensory  or affective  aspects  of pain
in  an experimental  model  of  peripheral  neuropathy.  Rats with  a spared  nerve  injury  (SNI)  model  of  neu-
ropathy  in  the  left  hind  limb  had  a  chronic  cannula  for microinjections  of  drugs  into  the  right amygdala
or  the internal  capsule  (a control  site).  Sensory  pain  was  assessed  by determining  mechanical  hypersen-
sitivity  with calibrated  monoﬁlaments  and  affective  pain  by  determining  aversive  place-conditioning.
Amygdaloid  treatment  with ML-204,  a TRPC4/C5  antagonist,  produced  a dose-related  (5–10 g)  antihy-ransient receptor potential channels 4 and persensitivity  effect,  without  obvious  side-effects.  Additionally,  amygdaloid  administration  of  ML-204
reduced  affective-like  pain  behavior.  In  the  internal  capsule,  ML-204  had  no  effect  on hypersensitivity
or  affective-like  pain  in  SNI  animals.  In  healthy  controls,  amygdaloid  administration  of  ML-204  failed  to
inﬂuence  pain  behavior  induced  by  mechanical  stimulation  or noxious  heat.  The  results  indicate  that  the
amygdaloid  TRPC4/C5  contribute  to maintenance  of  pain  hypersensitivity  and  pain  affect  in  neuropathy.
©  2015 Elsevier  Ireland  Ltd.  All  rights  reserved.. Introduction
Amygdala has an important role in primary emotions, such
s fear [10]. Amygdala, particularly its lateral capsular subdivi-
ion within the central nucleus (CeA), the main output pathway
o the brainstem, is also involved in processing and regulation of
Abbreviations: ANOVA, analysis of variance; DMSO, dimethylsulfoxide; CeA, cen-
ral  nucleus of the amygdala; i.c., internal capsule; i.t., intrathecal; SNI, spared nerve
njury; TRPC4/C5, transient receptor channel 4/5.
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E-mail address: antti.pertovaara@helsinki.ﬁ (A. Pertovaara).
1 These authors had an equal contribution to this work.
ttp://dx.doi.org/10.1016/j.neulet.2015.09.033
304-3940/© 2015 Elsevier Ireland Ltd. All rights reserved.emotional aspects of pain and, through its efferent brainstem pro-
jections, in descending control of spinal pain-relay neurons [14,16].
Recently, it was  demonstrated that among multiple amygdaloid
mechanisms involved in the control of anxiety-driven behaviors
are transient potential channels 4 and 5 (TRPC4/C5) that are mem-
bers of the TRPC1/4/5 subfamily and that gate afferent amygdaloid
inputs in the lateral nucleus of the amygdala [17,18]. The lateral
amygdala has direct and indirect projections through the basolat-
eral nucleus to the main amygdaloid output nucleus CeA [10]. It
may  be hypothesized that TRPC4/C5-expressing amygdaloid neu-
rons through projections to the CeA may  regulate amygdaloid
processing of nociception and thereby also amygdaloid outputs to
brainstem pain regulation centers. Since, the amygdala is involved
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Fig. 1. Effect of amygdaloid administration of ML-204, a TRPC4/C5 antagonist, on pain behavior in neuropathic animals. (A) Mechanical hypersensitivity 15 min  following
administration of ML-20. (B) Time course of mechanical antihypersensitivity effect by ML-204. (C) Affective-like pain behavior assessed using aversive place-conditioning
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n all graphs, vehicle (Veh) or ML-204 was administered into the right amygdala a
eference: the corresponding Veh-value).
oth in pain and affect and has reciprocal connections with the
ain system [14,16], it may  be speculated that amygdala in gen-
ral and amygdaloid TRPC4/C5 in particular might be among neural
ubstrates contributing to the comorbidity between affect, such as
nxiety, and chronic pain (e.g., see Ref. [2]). To test this hypothesis,
e assessed whether microinjection of a TRPC4/C5 antagonist ML-
04 [12] into the amygdala or a control injection site in the brain
nﬂuences pain hypersensitivity in animals with an experimental
odel of chronic neuropathy. The effect of blocking the amygdaloid
RPC4/C5 was separately assessed on the sensory component of
europathic pain by determining mechanical hypersensitivity and
n the affective component of neuropathic pain by determin-
ng aversive place-conditioning. For comparison, we  determined
hether blocking the amygdaloid TRPC4/C5 inﬂuences pain behav-
or in healthy controls.
. Materials and methods
.1. Animals
The experiments were performed with adult male Hannover-
istar rats (Harlan, Horst, The Netherlands) weighing 180–280 g.
he experimental protocols were approved by the Experimental
nimal Ethics Committee of the Provincial Government of South-
rn Finland (Hämeenlinna, Finland), and the experiments were
erformed according to the guidelines of European Communities
ouncil Directive of 22 September 2010 (2010/63/EU). All efforts
ere made to limit distress and to use only the number of animals
ecessary to produce reliable scientiﬁc data. Rats were housed in a
2-h light/dark cycle with food and water access ad libitum.
.2. Surgical procedures for producing neuropathy
For inducing neuropathy, the spared nerve injury (SNI) model,
s described by Decosterd and Woolf [5], was  adopted. Prior to
urgery, the rat was anesthetized with sodium pentobarbital (Orion
harma, Espoo, Finland), administered intraperitoneally at the dose
f 60 mg/kg. Further, doses of pentobarbitone were given at the
ose of 15–20 mg/kg as needed to keep the depth of anesthesia deep
nough so that the animal did not react to noxious stimulation. An
ncision was subsequently made into the skin on the lateral surface
f the left thigh, followed by a section through the biceps femoris
uscle to expose the sciatic nerve and its terminal branches: theural, common peroneal and tibial nerves. The common peroneal
nd tibial nerves were then tightly ligated with 4–0 silk, sectioned
istal to the ligation and 3–4 mm of the distal nerve stump was
emoved. The sural nerve was left intact. To prevent postopera-e shown in the graphs. Error bars represent S.E.M. (n = 5–6). *P < .05 (Tukey’s test;
tive pain, animals were treated subcutaneously with 0.01 mg/kg of
buprenorphine twice daily for 2–3 days and they were allowed to
recover for at least a week before the experiments. Only animals
with tactile allodynia-like hypersensitivity (hind limb withdrawal
threshold to monoﬁlament stimulation in the operated side ≤4 g,
which is below the lower 95% conﬁdence limit of the threshold in
unoperated control animals) were selected for this study. SNI model
produced mechanical hypersensitivity in all animals of the present
study.
2.3. Cannula insertion and drug injection procedure
The animals had a guide cannula for drug administration into
the right amygdala (contralateral to the peripheral nerve injury)
as described in detail earlier [19]. The rationale for choosing the
right amygdala was  that earlier results have suggested that the
right amygdala has a more important role in processing of pain-
related signals than the left amygdala [4,6], although not in all
conditions [20]. Moreover, another reason for choosing the right
amygdala as the treatment target was  that in the present study
mechanical hypersensitivity was  induced in the left hind limb and
the amygdala-induced descending control of mechanically evoked
pain is expected to be stronger in the contra- than ipsilateral limb
[3,8]. For placement of the guide cannula (26 gauge; Plastics One,
Roanoke, VA, USA), the skull was exposed and a hole drilled for its
placement under sodium pentobarbital anesthesia (60 mg/kg i.p.).
The desired center of injection in the right amygdala was  in the cap-
sule lateral of the CeA: 2.1 mm posterior from the bregma, 4.3 mm
lateral from the midline, and 7.8 mm  ventral from the dura mater
[15]. The control injection site was  in the right internal capsule:
2.1 mm posterior from bregma, 3.6 mm  lateral from the midline,
and 5.0 mm ventral from the dura mater. The tip of the guide can-
nula was  positioned 2 mm above the desired injection site. The
cannula was  ﬁxed into the skull using a dental screw and dental
cement. Drug administration to the brain and experimental proto-
cols started 1 week after ﬁxation of the guide cannula to the skull.
A dummy  cannula was placed in the guide cannula, except when
drug administrations were performed.
2.4. Drugs and their administration procedure
ML-204, a selective TRPC4/C5 antagonist [12], and dimethylsul-
foxide (DMSO), the vehicle, were purchased from Sigma–Aldrich
(St. Louis, MO,  USA). ML-204 was  dissolved in DMSO (100%) and
administered at the dose of 5 g or 10 g. Unilateral infusions of
ML-204, or an equivalent volume of vehicle, were made by using
33 gauge injection needles (Plastics One) connected to a 10 l
14 H. Wei  et al. / Neuroscience Letters 608 (2015) 12–17
Fig. 2. Effect of ML-204, a TRPC4/C5 antagonist, in the internal capsule (i.c.; control injections site) on mechanical hypersensitivity (A) and affective-like pain (B) in neuropathic
animals. Effect of amygdaloid administration of ML-204 on mechanically evoked pain behavior (C) and heat nociception (D) in healthy controls.
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amilton microsyringe (Hamilton Bonaduz AG, Bonaduz,
witzerland) by polyethylene (PE-10) tubing. The injection
eedles protruded 2.0 mm beyond the cannula tips and a 0.5 l
olume was injected. The animals were gently restrained during
he infusion procedure. The duration of injection was  30 s. Injection
eedle was retained within the cannula for an additional 20 s after
rug infusion to maximize diffusion and to prevent backﬂow of
he drug into the cannula. At the currently used injection volume,
he spread of injection is expected to be close to 1 mm [13] and
hereby cover not only the CeA but also the adjacent amygdaloid
ubnuclei. Therefore, the currently applied drug injection volume
llows concluding whether the drug-induced effect originates
n the amygdala rather than pinpointing the effect to one of its
ubnuclei.
.5. Assessment of the sensory-like component of pain behavior
Before assessment of pain behavior, the rats were habituated
o the testing conditions at least in three one-hour sessions dur-
ng three consecutive days. Mechanically evoked limb withdrawal
as considered an index of sensory-like pain and assessed both in
europathic animals and healthy controls using a calibrated series
f monoﬁlaments that in the current experiment produced forces
anging from 1 g to 10 g in nerve-injured animals or 4 g to 26 g in
ontrols (North Coast Medical, Inc. Morgan Hill, CA, USA). During
esting, rats were on a grid, free to move inside a transparent box.
he monoﬁlaments were applied below the grid to the foot pad
f the left hind limb with increasing force until the rat withdrew
ts hind limb. At each time point, the paw ipsilateral to the spinal
erve ligation was stimulated ﬁve times at each stimulus force
ith an ascending series of calibrated monoﬁlaments. At each stim-
lus force, the withdrawal response frequency was  determined.
hen the animal responded by withdrawing the limb to each of
he ﬁve repetitive monoﬁlament stimulations, the response ratefor Fig. 1.
to the studied stimulus force was  consider to be 100%. When the
animal did not withdraw to any of the ﬁve repetitive stimulations,
the response rate to the studied stimulus force was considered to
be 0%. An increase in the withdrawal response rate was considered
to represent mechanical hypersensitivity effect.
In healthy controls, mechanical pain was  assessed as described
above. Moreover, sensory-like heat pain was  assessed in healthy
controls by determining limb withdrawal latency induced by nox-
ious heat applied to the plantar skin using radiant heat equipment
(Plantar test model 7370, Ugo Basile, Varese, Italy). The cut-off point
was set at 15 s.
2.6. Assessment of the affective-like component of pain behavior
Place-avoidance test was performed in neuropathic animals, as
described earlier [9], to obtain a measure of affective-like pain.
Before testing, the animals were habituated to test conditions by
spending 1–2 h daily for 2 days in the test box. In the actual test-
ing, the rat was placed within a Plexiglas chamber (60 × 30 × 30 cm)
one half of which was painted black on the external surface placed
upon an elevated metal grid. The rats were placed over the mid-
line of the chamber and stimulation of the plantar surface of the
hind paw initiated with a 26 g monoﬁlament once every 15 s for
20 min. When residing within the dark side of the chamber the
hind paw of the nerve-injured limb was stimulated. Conversely,
the non-operated hind paw was stimulated when residing within
the light side of the chamber. Throughout the 20 min test period
rats were allowed unrestricted movement throughout the cham-
ber. The percent time spent in the dark side of the chamber during
the observation period was determined in each condition for each
animal. It is assumed that the more aversive the mechanical stim-
ulation of the hind paw, the more the animal spends time in the
light side of the chamber.
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ites  are shown with one symbol. CeA, central nucleus of the amygdala; BLA, basola
.7. Course of study
There were three separate groups of animals: (i) SNI animals
ith a cannula in the right amygdala, (ii) SNI animals with a can-
ula in the right internal capsule, (iii) healthy controls with a
annula in the right amygdala. Experiments were performed at
east a week following unilateral installation of the brain cannula
nto the right amygdala or internal capsule. Mechanically induced
imb withdrawal, heat-evoked limb withdrawal and aversive place-
onditioning were evaluated on separate days. Pain behavior was
ested in the following drug-treatment conditions: vehicle, ML-
04 at the dose of 5 g or 10 g. Limb withdrawal responses were
ssessed 5, 15, 30, and 60 min  after drug administration as well
s before it, while place-avoidance was continuously assessed for
0 min  after drug administration. The order of testing the drug
onditions was varied to avoid serial effects. The interval between
esting the different experimental conditions in the same animal
as two days.
.8. Histology
At the end of the experiment, rats were sacriﬁced by an overdose
f pentobarbital and the brain was removed and immersed in 4%
ormaldehyde. Coronal sections of the brain were cut to verify the
ite of injection according to the atlas of Paxinos and Watson [15].
.9. Statistical analysesData were analyzed using one-way or two-way ANOVA followed
y Tukey’s test, or by t-test. P < .05 was considered to represent a
igniﬁcant difference.daloid injection site in a nerve-injured animal; each asterisk represents a control
ts an amygdaloid injection site in a healthy control animal. Overlapping injections
nucleus of the amygdala; LA, lateral nucleus of the amygdala; i.c., internal capsule.
3. Results
3.1. Effect on pain behavior of neuropathic animals by
amygdaloid administration of ML-204
Microinjection of ML-204 (an antagonist of the TRPC4/C5 chan-
nels) at doses 0 g (vehicle control), 5 g, and 10 g into the right
amygdala of neuropathic animals produced a dose-related mechan-
ical antihypersensitivity effect in the injured left limb (F2,84 = 18.04,
P < .0001; Fig. 1A). The onset of the antihypersensitivity effect
occurred within 5 min, the maximum effect was reached at 15 min,
and the effect disappeared by 60 min  (Fig. 1B). In the aversive
place-conditioning test, ML-204 in the amygdala reduced affective-
like pain behavior as indicated by the reduction in time spent in
light (F2,14 = 4.83, P = .025; Fig. 1C). The suppression of affective-like
pain behavior induced by amygdaloid administration of ML-204
at a dose of 5 g was of equal magnitude as at the dose of 10 g
(Fig. 1C). No obvious side-effects were observed following amyg-
daloid administration of ML-204 at doses 5–10 g.
3.2. Effect on pain behavior of neuropathic animals by ML-204 at
a control injection site
Microinjection of ML-204 (10 g) into the control injection site,
the right internal capsule, failed to attenuate mechanical hypersen-
sitivity (F1,48 = 2.72; Fig. 2A). Moreover, ML-204 at the dose of 10 g
failed to inﬂuence aversive place-conditioning (t9 = 0.59; Fig. 2B).
3.3. Effect of amygdaloid administration of ML-204 on pain
behavior in healthy controls
In healthy controls, administration of ML-204 (10 g) into
the right amygdala failed to inﬂuence pain behavior induced by
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echanical stimulation (F1,60 = 0.02; Fig. 2C) or noxious heating
t10 = 0; Fig. 2D).
.4. Centers of brain injection sites
The centers of the amygdaloid injection sites were in or imme-
iately adjacent to the CeA in the right hemisphere (Fig. 3). The
enters of control injection sites were in the right internal capsule
Fig. 3).
. Discussion
The present results indicate that pharmacological block-
ng of the TRPC4/C5 in the amygdala attenuates sensory- and
ffective-like pain in neuropathy as indicated by the mechanical
ntihypersensitivity effect and the decrease of time spent in light
n the aversive place-conditioning test, respectively. The currently
sed microinjection volume of 0.5 l does not allow pinpointing
he critical site of drug action at a subnucleus level. However, the
nding that the TRPC4/C5 antagonist failed to inﬂuence pain behav-
or of neuropathic animals when microinjected into a control site,
he internal capsule, supports the interpretation that the TRPC4/C5
ntagonist-induced suppression of neuropathic pain behavior in
he present study was due to action on the amygdala rather than
lsewhere in the brain. In line with this, it has been shown that
RPC4/C5 in the amygdala are expressed particularly in the lateral
ucleus [17,18], which has direct and indirect intra-amygdaloid
rojections to the CeA [10], the main sensory output nucleus that
s involved in processing of pain-related signals and that through
ts connections to the brainstem can contribute to the descending
ontrol of pain [14,16].
Pharmacological blocking of the amygdaloid TRPC4/C5 failed
o inﬂuence pain behavior in healthy controls. This ﬁnding sug-
ests that in chronic painful neuropathy a change in the function of
mygdala takes place, after which the amygdaloid TRPC4/C5 have
 signiﬁcant pain facilitatory effect. Chronic neuropathy, includ-
ng that induced by the currently used experimental animal model,
s known to induce anxiety that is associated with ongoing pain
nd pain hypersensitivity [11]. Moreover, blocking the amygdaloid
RPC4/C5 was shown to reduce anxiety in earlier studies [17,18,22]
nd suppress neuropathic pain behavior in the present study.
ogether these ﬁndings suggest that the amygdaloid TRPC4/C5 are
mong potential underlying mechanisms for comorbidity of pain
nd affect in chronic neuropathy.
While the effects of amygdaloid TRPC4/C5 on neuropathic pain
ave not been studied earlier, there are earlier studies that have
ssessed pain behavior in various pain models following sys-
emic pharmacological blocking of TRPC4/C5 or genetic blocking
f the TRPC4. These studies have demonstrated that e.g., chemi-
ally induced bladder overactivity and visceral pain are reduced by
 systemic block of TRPC4/C5 [1,21], which effects may, at least
artly be explained by a peripheral action [21]. Only negligible
ifferences were observed in somatically induced pain behavior
r in the effect of joint inﬂammation between control and TRPC4
nockout rats [21]. It is noteworthy that a model of peripheral neu-
opathy induced by constriction injury of the sciatic or trigeminal
erve failed to show markedly different pain behavior between
ontrols and TRPC4 knockout rats [21], whereas pharmacological
lock of the amygdaloid TRPC4/C5 in the SNI model of neuropathy
ttenuated hypersensitivity in the present study. Among potential
xplanations for this difference are that genetic blocking affecting
RPC4 only and pharmacological blocking inﬂuencing amygdaloid
RPC4 and TRPC5 may  have different effects on neuropathic pain
r that constriction injury and SNI models of neuropathy induce at
east partly different pathophysiological changes in the central pain
[tters 608 (2015) 12–17
signaling system [7]. Additionally, various differences in experi-
mental conditions, such as the methods for assessing sensory- and
affective-like pain or local amygdaloid versus systemic blocking of
channels may  have contributed to the difference.
5. Conclusions
The present results suggest that the amygdaloid TRPC4/C5 that
in earlier studies were shown to be involved in control of innate
fear [17,18] contribute to regulation of pain hypersensitivity and
pain affect in neuropathy. It is hypothesized that the amygdaloid
TRPC4/C5 might exert a role in comorbidity between affect and
chronic pain and thereby, they might provide therapeutic targets in
affective disorder-associated chronic neuropathic pain conditions.
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